WO2019141957A1 - Dérivés d'hydroxy pyrazole n-pyrimidinyle et utilisations associées - Google Patents

Dérivés d'hydroxy pyrazole n-pyrimidinyle et utilisations associées Download PDF

Info

Publication number
WO2019141957A1
WO2019141957A1 PCT/GB2018/050171 GB2018050171W WO2019141957A1 WO 2019141957 A1 WO2019141957 A1 WO 2019141957A1 GB 2018050171 W GB2018050171 W GB 2018050171W WO 2019141957 A1 WO2019141957 A1 WO 2019141957A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
spp
optionally substituted
group
het
Prior art date
Application number
PCT/GB2018/050171
Other languages
English (en)
Inventor
Simon Ross Crumpler
William DALBY-BROWN
Thomas David Pallin
John Bondo Hansen
Anne-Marie Lund WINTHER
Original Assignee
Cado Biotechnology Ivs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cado Biotechnology Ivs filed Critical Cado Biotechnology Ivs
Priority to PCT/GB2018/050171 priority Critical patent/WO2019141957A1/fr
Publication of WO2019141957A1 publication Critical patent/WO2019141957A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/56—1,2-Diazoles; Hydrogenated 1,2-diazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides
    • A01N47/42—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides containing —N=CX2 groups, e.g. isothiourea
    • A01N47/44—Guanidine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to uses of certain /V-pyrimidinyl hydroxy pyrazoles, and pharmaceutically acceptable salts and/or prodrugs thereof, which compounds have been found to be potent inhibitors of fungal growth. As such, these compounds are of use in the treatment or prevention of fungal infections and associated diseases, and in other applications requiring the inhibition of fungal growth. Such compounds have also been found to have antibacterial properties, redering them of use in the treatment or prevention of bacterial infections.
  • the present invention relates to the use of such compounds as medicaments and agrochemicals, to pharmaceutical and agrochemical compositions containing such compounds, and to processes for the production of such compositions. Further, the present invention relates to certain novel compounds and synthetic processes for their production.
  • Severe systemic fungal infection in hospitals (such as candidiasis, aspergillosis, fusariosis, histoplasmosis, blastomycosis, coccidioidomycosis and scedosporiosis; see, for example, Chapman et ai, Trans Am Clin Climatol Assoc., 119, 197-215 (2008)) is commonly seen in neutropenic patients following chemotherapy, in other oncology patients with immune suppression, and in patients who are immune-compromised due to, for example, Acquired Immune Deficiency Syndrome (AIDS) caused by HIV infection, as well as in patients in intensive care. Serious fungal infections may cause 5-10% of deaths in patients undergoing lung, pancreas or liver transplantation (Ribaud et al., Clin Infect Dis., 28, 322- 30 (1999)).
  • AIDS Acquired Immune Deficiency Syndrome
  • invasive aspergillosis remains a major cause of morbidity and death in neutropenic patients with hematologic malignancies, especially in patients undergoing induction chemotherapy and hematopoietic stem cell transplantation. Indeed, despite recent advances in antifungal therapy, the overall mortality rate in patients with invasive pulmonary aspergillosis remains very high, approaching 90%.
  • Mucormycosis is a highly lethal infection caused by fungi belonging to the order Mucorales of the class Zygomycetes (Spellberg B et al. , Clin Microbiol Rev, 18(3), 556-569 (2005)). Recent data have demonstrated a striking increase in the frequency of mucormycosis cases. Unfortunately, despite aggressive surgical debridement and antifungal therapy, mortality from mucormycosis remains at least 50% (Ibrahim, A. S. et al., Journal of Clinical Investigation, 117(9), 2649-2657 (2007)).
  • Risk factors associated with candidemia and/or systemic candidiasis include granu locytopenia, bone marrow transplantation, solid organ transplantation (e.g. liver, kidney), parenteral hyperalimentation, solid neoplasms, corticosteroids, broad-spectrum antibiotics, burns, prolonged ICU (intensive care units) stay (i.e.
  • antifungal drug e.g. amphotericin B
  • the azoles e.g. voriconazole, fluconazole, posaconazole, ketoconazole or itraconazole
  • the echinocandins e.g. caspofungin, micafungin or anidulafungin
  • flucytosine e.g. flucytosine
  • polyenes are the oldest class of antifungal agents, having been first introduced in the 1950s. The exact mode of action remains unclear, but polyenes are only effective against fungal organisms that contain ergosterols in their outer membranes. It has been proposed that amphotericin B interacts with fungal membrane ergosterols, leading to pore formation, which in turn results in leakage of cytoplasmic components and subsequent cell death. Azoles inhibit fungal growth by inhibition of CYP51A1 (lanosterol C14a-demethylase) . This leads to a depletion of the membrane ergosterol and the accumulation of ergosterol precursors resulting in a plasma membrane with altered fluidity and structure.
  • CYP51A1 lanosterol C14a-demethylase
  • Echinocandins work by inhibition of the enzyme 1 ,3 ⁇ -glucan synthase, responsible for synthesis of b-glucans in the fungal cell wall. This leads to abnormal cell wall formation, osmotic sensitivity and cell lysis.
  • Flucytosine is a pyrimidine analogue interfering with the cellular pyrimidine metabolism as well DNA, RNA and protein synthesis.
  • widespread resistance to flucytosine limits its therapeutic use.
  • the present invention relates to compounds that are /V-pyrimidinyl substituted hydroxy pyrazoles, and pharmaceutically acceptable salts thereof. Although certain such compounds have been previously described, there is no disclosure of the use of such compounds as anti-fungal agents.
  • R 1 and R 2 each independently represent H or a substituent selected from the group consisting of
  • each of R 1a to R 1 k independently represent H, Ar 3 , Het 3 , C1 -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6 cycloalkyl or C5-6 cycloalkenyl, wherein the latter five groups are optionally substituted, where possible, by one or more A 3 ; each of R 1a to R 1 k independently represent H, Ar 3 , Het 3 , C1 -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6 cycloalkyl or C5-6 cycloalkenyl, wherein the latter five groups are optionally substituted, where possible, by one or more A 3 , or any pair of R 1c and R 1d , R 1e and R 1f , R 19 and R 1 h , and R 1j and R 1 k may, together with the atom(s) to which they are attached, form a 4- to -14- membered heterocycloalky
  • each of A 1 to A 6 independently represent a substituent selected from the group consisting of
  • each of Ar 1 to Ar 5 independently represents a Ce-io carbocyclic aromatic group optionally substituted with one or more substituents selected from B 1 ; each of Het 1 to Het 5 independently represents:
  • each of D 1 to D 3 independently represents a group selected from halo, oxy, -NO2, -CN, - OR 6a , -N(R 6b )(R 6c ), -C(0)0R 6d , -C(0)NR 6e R 6f , Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C5-6 cycloalkenyl and phenyl, wherein the latter six groups are optionally substituted, where possible, by one or more fluoro; or wherein D 1 represents Het 10 ;
  • Het 10 represents:
  • each X 5 individually represents a group selected from oxy or a Ci-e alkyl, wherein the Ci-e alkyl is optionally substituted by OH; each of R 5a to R 5f and R 6a to R 6f independently represents a group selected from Ci-e alkyl, H and phenyl, wherein the latter two groups are optionally substituted by one or more group selected from halo, -NH 2 and -OH, Ci-e alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6 cycloalkyl and C5-6 cycloalkenyl, wherein the latter five groups are optionally substituted, where possible, by one or more group selected from halo, oxy, -NH 2 and -OH; and each p, q and r independently represents 0, 1 or 2, which compounds may be
  • a method for the treatment or prevention of a fungal and/or bacterial infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt and/or prodrug thereof.
  • references herein to particular aspects of the invention will include references to all embodiments and particular features thereof. Further, any one or more embodiments and/or particular features of any aspect of the invention may be combined with any one or more other such embodiments in order to form more particular embodiments and/or features of that aspect of the invention, without departing from the disclosure of the invention as provided herein.
  • pharmaceutically acceptable salt includes references to pharmaceutically acceptable salts formed with either acids or bases (i.e. acid-formed proton addition salts or base-formed proton removal salts).
  • Particular pharmaceutically acceptable salts include acid addition salts, such as carboxylate salts (e.g. formate, acetate, trifluoroacetate, propionate, isobutyrate, heptanoate, decanoate, caprate, caprylate, stearate, acrylate, caproate, propiolate, ascorbate, citrate, glucuronate, glutamate, glycolate, a-hydroxybutyrate, lactate, tartrate, phenylacetate, mandelate, phenylpropionate, phenylbutyrate, benzoate, chlorobenzoate, methylbenzoate, hydroxybenzoate, methoxybenzoate, dinitrobenzoate, o-acetoxybenzoate, salicylate, nicotinate, isonicotinate, cinnamate, oxalate, malonate, succinate, suberate, sebacate, fumarate, malate, maleate, hydroxymaleate, hippur
  • sulfonate salts e.g. benzenesulfonate, methyl-, bromo- or chloro-benzenesulfonate, xylenesulfonate, methanesulfonate, ethanesulfonate, propanesulfonate, hydroxyethanesulfonate, 1- or 2- naphthalene-sulfonate or 1 ,5-naphthalenedisulfonate salts) or sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate or nitrate salts.
  • sulfonate salts e.g. benzenesulfonate, methyl-, bromo- or chloro-benzenesulfonate, xylenesulfonate, methanesulfonate,
  • TFA trifluoroacetate
  • HCI hydrochloride salts
  • mono- or di- salts i.e. formed using one or two equivalents of the acid, respectively
  • base addition salts include salts formed with alkali metals (such as Na and K salts), alkaline earth metals (such as Mg and Ca salts), organic bases (such as ethanolamine, diethanolamine, triethanolamine, tromethamine and lysine) and inorganic bases (such as ammonia and aluminium hydroxide). More particularly, base addition salts that may be mentioned include Mg, Ca and, most particularly, K and Na salts.
  • Such salts may be formed by conventional means, for example by reaction of a free acid or a free base form of a compound of formula I with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. in vacuo , by freeze-drying or by filtration). Salts may also be prepared by exchanging a counter-ion of a compound of the invention in the form of a salt with another counter-ion, for example using a suitable ion exchange resin.
  • Compounds of the invention may contain double bonds and may thus exist as E (entussi) and Z ( Milton ) geometric isomers about each individual double bond. All such isomers and mixtures thereof are included within the scope of the invention.
  • Compounds of the invention may also contain one or more asymmetric carbon atoms and may therefore exhibit optical and/or diastereoisomerism.
  • Enantiomers and diastereoisomers may be isolated using conventional techniques, e.g. chromatography or fractional crystallisation.
  • the various stereoisomers may be isolated by separation of a racemic or other mixture of the compounds using conventional, e.g. fractional crystallisation or HPLC, techniques.
  • the desired optical isomers may be made by reaction of the appropriate optically active starting materials under conditions which will not cause racemisation or epimerisation (i.e.
  • a‘chiral pool’ method by reaction of the appropriate starting material with a‘chiral auxiliary’ which can subsequently be removed at a suitable stage, by derivatisation (i.e. a resolution, including a dynamic resolution), for example with a homochiral acid followed by separation of the diastereomeric derivatives by conventional means such as chromatography, or by reaction with an appropriate chiral reagent or chiral catalyst all under conditions known to the skilled person. All stereoisomers and mixtures thereof are included within the scope of the invention.
  • the present invention also embraces isotopically-labelled compounds of the first aspect of the invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature (or the most abundant one found in nature). All isotopes of any particular atom or element as specified herein are contemplated within the scope of the compounds of the invention.
  • the compounds described herein also include deuterated compounds, i.e. in which one or more hydrogen atoms are replaced by the hydrogen isotope deuterium.
  • Ci -Z alkyl groups (where z is the upper limit of the range) defined herein may be straight-chain or, when there is a sufficient number (i.e. a minimum of two or three, as appropriate) of carbon atoms, be branched-chain.
  • a C 3-z -cycloalkyl group (where z is the upper limit of the range) may be monocyclic or bicyclic and may further be bridged. Further, when there is a sufficient number (i.e. a minimum of four) of carbon atoms, such cycloalkyl groups may also be part cyclic. Where the number of carbon atoms permits, cycloalkyl groups may also be spiro- groups (i.e. two cycloalkyl rings linked together by a single common carbon atom).
  • Ci -Z alkenyl groups (where z is the upper limit of the range) defined herein may be straight-chain or, when there is a sufficient number (i.e. a minimum of two or three, as appropriate) of carbon atoms, be branched-chain.
  • a Cs- z -cycloalkenyl group (where z is the upper limit of the range) may be monocyclic or bicyclic and may further be bridged. Further, when there is a sufficient number (i.e. a minimum of six) of carbon atoms, such groups may also be part cyclic.
  • Ci -Z alkynyl groups (where z is the upper limit of the range) defined herein may be straight-chain or, when there is a sufficient number (i.e. a minimum of four) of carbon atoms, be branched-chain.
  • halo refers to a halogen group, such as fluoro, chloro, bromo and iodo (e.g. fluoro and chloro and bromo).
  • the term“halo” may refer to a fluoro or chloro group (e.g. F).
  • the term“oxy”, when used herein, refers to a carbonyl (i.e. 0) group. The skilled person will understand that such oxy groups, where present, will only be present at suitable positions on the group to which they are attached, i.e. on suitable, saturated carbon atoms (e.g. forming ketone or aldehyde moieties).
  • such oxy substituents may be present, in particular, on alkyl, cycloalkyl, alkenyl, cycloalkenyl and alkynyl groups (i.e. on saturated carbon atoms present therein) or on alkyl moieties forming part of aryl, heteroaryl or heterocycloaryl groups as described herein (in which case, references to other instances of such substitution may be removed).
  • alkyl, cycloalkyl, alkenyl, cycloalkenyl and alkynyl groups i.e. on saturated carbon atoms present therein
  • alkyl moieties forming part of aryl, heteroaryl or heterocycloaryl groups as described herein (in which case, references to other instances of such substitution may be removed).
  • refereneces to oxy substituents may be deleted throughout.
  • Heterocycloalkyl groups (e.g. where representing a Het group, such as Het 1 , as defined herein) group that may be mentioned include saturated monocyclic and bicyclic heterocycloalkyl groups (which groups may further be bridged) in which at least one (e.g. one to four) of the atoms in the ring system is other than carbon (i.e. a heteroatom, such as boron, nitrogen, oxygen or sulphur), and in which the total number of atoms in the ring system is as defined (e.g. from four to fourteen).
  • a heteroatom such as boron, nitrogen, oxygen or sulphur
  • heterocycloalkyl groups that may be mentioned include those in which the total number of atoms in the ring system is from four to twelve, such as from five to twelve (e.g. from five to ten and, most particularly, from five to six, so forming a 5- or 6- membered heterocycloalkyl group). More particular heterocycloalkyl groups that may be mentioned include those containing one, two or three heteroatoms (e.g. one or two heteroatoms, such as one heteroatom), such as boron and two oxygens (i.e. as a boronate ester), one or two nitrogens, one or two sulphurs, one or two oxygens, or one oxygen and one nitrogen, such as those in which the total number of atoms in the ring system is five or six.
  • heteroatoms e.g. one or two heteroatoms, such as one heteroatom
  • boron and two oxygens i.e. as a boronate ester
  • heterocycloalkenyl groups e.g. where representing a Het group, such as Het 1 , as defined herein
  • group that may be mentioned include unsaturated (but non-aromatic) monocyclic and bicyclic heterocycloalkyl groups (which groups may further be bridged) in which at least one (e.g. one to four) of the atoms in the ring system is other than carbon (i.e. a heteroatom, such as boron, nitrogen, oxygen or sulphur), and in which the total number of atoms in the ring system is as defined (e.g. from four to fourteen).
  • unsaturated (but non-aromatic) monocyclic and bicyclic heterocycloalkyl groups which groups may further be bridged) in which at least one (e.g. one to four) of the atoms in the ring system is other than carbon (i.e. a heteroatom, such as boron, nitrogen, oxygen or sulphur), and in which the total number of atoms in
  • heterocycloalkenyl groups that may be mentioned include those in which the total number of atoms in the ring system is from five to twelve, such as from five to twelve (e.g. from five to ten and, most particularly, from five to six, so forming a 5- or 6- membered heterocycloalkenyl group). More particular heterocycloalkenyl groups that may be mentioned include those containing one, two or three heteroatoms (e.g. one or two heteroatoms, such as one heteroatom), such as one or two nitrogens, one or two (e.g. one) sulphur(s), one or two (e.g. one) oxygen(s), or one oxygen and one nitrogen, such as those in which the total number of atoms in the ring system is five or six.
  • heteroatoms e.g. one or two heteroatoms, such as one heteroatom
  • Heterocycloalkyl and heterocycloalkenyl groups (e.g. where representing a Het group as defined herein) that may be mentioned include 7-azabicyclo-[2.2.1]heptanyl, 6- azabicyclo[3.1.1]heptanyl, 6-azabicyclo[3.2.1 ]-octanyl, 8-azabicyclo[3.2.1]octanyl, aziridinyl, azetidinyl, dihydropyranyl, dihydropyridyl, dihydropyrrolyl (including 2,5- dihydropyrrolyl), dioxolanyl (including 1 ,3-dioxolanyl), dioxanyl (including 1 ,3-dioxanyl and 1 ,4-dioxanyl), dithianyl (including 1 ,4-dithianyl), dithiolanyl (including 1 ,3-dithiolanyl), imidazolidinyl,
  • Substituents on heterocycloalkyl and heterocycloalkenyl groups may, where appropriate, be located on any atom in the ring system including, where possible, a heteroatom. Further, in the case where the substituent is another cyclic compound, then the cyclic compound may be attached through a single atom on the heterocycloalkyl group, forming a so-called“spiro”-compound.
  • the point of attachment of heterocycloalkyl groups may be via any atom in the ring system including (where appropriate) a heteroatom (such as a nitrogen or boron atom), or an atom on any fused carbocyclic ring that may be present as part of the ring system.
  • Heterocycloalkyl groups may also be in the N- or S- oxidised form.
  • heteroatom(s) as used herein shall include references to boron, oxygen, nitrogen and sulphur (e.g. oxygen, nitrogen and sulphur).
  • a heterocycloalkyl group is preferably a 5- or 6-membered heterocycloalkyl group.
  • a heterocycloalkenyl group is preferably a 5- or 6-membered heterocycloalkyl group.
  • bicyclic refers to groups in which the second ring of a two-ring system is formed between two adjacent atoms of the first ring.
  • bridged refers to monocyclic or bicyclic groups in which two non-adjacent atoms are linked by either an alkylene or heteroalkylene chain (as appropriate).
  • Carbocyclic aromatic groups (which may also be referred to as aryl groups; e.g. where representing an Ar group, such as Ar 1 , as defined herein) that may be mentioned include those containing from six to fourteen atoms (i.e. carbon atoms) in the ring (which may be referred to as Ce- M groups).
  • Particular carbocyclic aromatic groups that may be mentioned include Ce-io (e.g. Ce) groups.
  • Such groups may be monocyclic or bicyclic, in which at least one ring is aromatic.
  • aryl groups that may be mentioned include phenyl, naphthyl and the like, such as 1 ,2,3,4-tetrahydronaphthyl, indanyl, indenyl and fluorenyl.
  • the point of attachment of aryl groups may be via any atom of the ring system.
  • aryl groups are bicyclic or tricyclic, they are preferably linked to the rest of the molecule via an aromatic ring.
  • Particular carbocyclic aromatic groups i.e. aryl groups; e.g. where representing an Ar group as defined herein
  • aryl groups e.g. where representing an Ar group as defined herein
  • Particular carbocyclic aromatic groups include phenyl and naphthyl.
  • carbocyclic aromatic groups i.e. aryl groups; e.g. where representing an Ar group as defined herein
  • aryl groups e.g. where representing an Ar group as defined herein
  • Heteroaryl groups include those having from 5 to 14 (e.g. from 5 to 10, or 5 or 6) ring members. Such groups may be monocyclic, bicyclic or tricyclic, provided that at least one of the rings is aromatic and wherein at least one (e.g. one to three) of the atoms in the ring system is other than carbon (i.e. a heteroatom, such as nitrogen, oxygen or sulphur).
  • a heteroaryl group as described herein contains more than one ring (e.g. is bicyclic) and one or more (e.g.
  • Heteroaryl groups include oxazolopyridyl (including oxazolo[4,5-b]pyridyl, oxazolo[5,4-b]pyridyl and, in particular, oxazolo[4,5-c]pyridyl and oxazolo[5,4-c]pyridyl), thiazolopyridyl (including thiazolo[4,5-b]pyridyl, thiazolo[5,4-b]pyridyl and, in particular, thiazolo[4,5- c]pyridyl and thiazolo[5,4-c]pyridyl), benzothiadiazolyl (including 2, 1 ,3-benzothiadiazolyl), iso
  • heteroaryl groups that may be mentioned include furanyl, pyridinyl, triazolyl (including 1 ,2,4-triazolyl), pyrimidinyl and oxadiazolyl (including 1 ,2,4-oxadiazolyl and 1 ,3,4-oxadiazolyl).
  • heteroaryl groups that may be mentioned include those bound (to the remainder of the compound) via a heteroatom (e.g. bound via a nitrogen atom, as comprised in the heteroaryl group).
  • heteroaryl groups may, where appropriate, be located on any atom in the ring system including, where possible, a heteroatom.
  • the point of attachment of heteroaryl groups may be via any atom in the ring system including (where appropriate) a heteroatom (such as a nitrogen atom), or an atom on any fused carbocyclic ring that may be present as part of the ring system.
  • heteroaryl groups when heteroaryl groups are polycyclic, they are preferably linked to the rest of the molecule via an aromatic ring.
  • Heteroaryl groups may also be in the N- or S- oxidised form.
  • the aryl or heteroaryl group is partly aromatic, i.e. the aryl or heteroaryl group consists of at least two rings where at least one ring is not aromatic.
  • the identity of two or more substituents in a compound of the first aspect of the invention may be the same, the actual identities of the respective substituents are not in any way interdependent.
  • the identity of those groups is in no way interdependent.
  • the identities of those individual substituents are not to be regarded as being interdependent.
  • the identities of the two R 1a groups are not to be regarded as being in any way interdependent.
  • R 1a to R 1k this will be understood by the skilled person to mean R 1a , R 1 b , R 1c , R 1d , R 1 e , R 1f , R 19 , R 1 h , R 1 i , R 1j and R 1 k , inclusively.
  • R 1 is not H (i.e. R 1 is a group other than H).
  • R 1 represents Ar 1 , Het 1 , C 1-6 alkyl, C 2-6 alkenyl, C ⁇ alkynyl, C 3-6 cycloalkyl or C 5-6 cycloalkenyl, wherein the latter five groups are optionally substituted, where possible, by one or more A 1 .
  • R 1 represents Ar 1 , Het 1 , C 1-6 alkyl or C 1-6 cycloalkyl, wherein the latter two groups are optionally substituted by one or more A 1 .
  • the Ar 1 group represents phenyl optionally substituted with one or more B 1 .
  • the Ar 1 group represents phenyl optionally substituted with one or more (e.g. one or two) groups selected from halo (e.g. F and Cl) and -CN.
  • the Het 1 group represents:
  • a 5- to 6- membered heteroaryl group optionally substituted with one or more substitutent selected from B 2 (e.g. wherein B 2 represents C1-3 alkyl, such as methyl or ethyl) or
  • a 5- to 6- membered heterocycloalkyl or heterocycloalkenyl group e.g. a 5- to 6- membered heterocycloalkyl group
  • a 5- to 6- membered heterocycloalkyl group optionally substituted with one or more substitutent selected from B 3 .
  • R 1 represents Ci-e alkyl
  • the C alkyl group is optionally substituted with one or more group selected from halo and, in particular, Ar 5 (e.g. wherein Ar 5 represents phenyl optionally substituted with one or more B 1 ), Het 5 , and -OR 3a (e.g. wherein R 3a represents methyl).
  • Ar 5 e.g. wherein Ar 5 represents phenyl optionally substituted with one or more B 1
  • Het 5 e.g. wherein R 3a represents methyl
  • -OR 3a e.g. wherein R 3a represents methyl
  • such Ci-e alkyl groups may represent, in particular, corresponding C1-3 alkyl groups (e.g. methyl).
  • R 1 represents Ci-e cycloalkyl
  • the Ci-e cycloalkyl group is optionally substituted with one or more halo (e.g. one or more F) or, more particularly, is unsubstituted.
  • R 1 represents alkyl
  • the substituents on R 1 groups do not include fluoro
  • R 1 represents alkyl
  • the substituents on R 1 groups do not include halo.
  • R 1 represents alkyl
  • the R 1 group is unsubstituted.
  • R 1 represents a 5- to 6- membered heteroaryl group optionally substituted with one or more substitutent selected from B 2 (e.g. wherein B 2 represents Ci- 3 alkyl, such as methyl or ethyl).
  • B 2 represents Ci- 3 alkyl, such as methyl or ethyl
  • the heteroaryl group may be optionally substituted with two C1-3 alkyl groups.
  • R 2 represents H, halo (e.g. F, Cl or Br, such as Cl or Br), C1-3 alkyl optionally substituted with one or more A 1 (e.g. wherein A 1 represents -CN) or -N(R 1g )R 1 h (e.g. wherein R 1 9 represents H and R 1 h represents C1-2 alkyl optionally substituted with one or more oxy, such as to form a -NHC(0)CH3 group).
  • halo e.g. F, Cl or Br, such as Cl or Br
  • a 1 represents e.g. wherein A 1 represents -CN
  • -N(R 1g )R 1 h e.g. wherein R 1 9 represents H and R 1 h represents C1-2 alkyl optionally substituted with one or more oxy, such as to form a -NHC(0)CH3 group.
  • R 2 does not represent Ar 1 or Het 1 .
  • R 2 represents H
  • R 3 represents H or fluoro.ln a more particular embodiment, R 3 represents H.
  • R 5 represents H or fluoro. In a more particular embodiment, R 5 represents H.
  • R 3 and R 5 are each H or fluoro. In more particular embodiments of the first aspect of the invention, R 3 and R 5 are each H.
  • R 2 , R 3 and R 5 are each H or fluoro. In further embodiments of the first aspect of the invention, R 2 , R 3 and R 5 are each H.
  • R 1 and R 4 are as defined herein (i.e. in the first aspect of the invention, including all embodiments thereof).
  • R 4 represents H or, particularly, a substituent selected from the group consisting of Het 2 , halo, -N0 2 , -OR 2a , -S(0) P R 2b , -S(0) q N(R 2c )(R 2d ), -N(R 2e )S(0) r R 2f and -N(R 29 )(R 2h ).
  • R 4 is a group bound to the remainder of the compound (i.e. bound to the core pyrazole moiety) via a heteroatom (e.g. via a nitrogen atom).
  • R 4 represents H or, particularly, a substituent selected from the group consisting of Het 2 (e.g. wherein Het 2 is bound via a nitrogen atom), -OR 2a (e.g. -OH) and -N(R 29 )(R 2h ).
  • the -N(R 29 )(R 2h ) group is a -NHR 2h group (i.e. R 29 represents H) , such as wherein R 2h represents C 1-3 alkyl (e.g. C 1-2 alkyl) optionally substituted with one or more A 5 (such as wherein A 5 represents Ar 5 , Het 5 , halo, -OR 3a , -N(R 39 )R 3h , -C(0)0R 3i or -C(0)NR 3 iR 3k .
  • the Het 2 group may in particular represent a 5- to 14- membered heteroaryl group (e.g. a 5- to 6- membered heteroaryl group) optionally substituted by one or more substituents selected from B 2 .
  • B 2 groups that may be mentioned include halo (e.g. fluoro), -OR 4a (e.g. -OCH 3 ) and C 1-6 alkyl (e.g. C 1-3 alkyl, such as C 1 alkyl) optionally substituted by one or more fluoro.
  • halo e.g. fluoro
  • -OR 4a e.g. -OCH 3
  • C 1-6 alkyl e.g. C 1-3 alkyl, such as C 1 alkyl
  • R 4 represents H or, particularly, a substituent selected from the group consisting of -OR 2a and -N(R 29 )(R 2h ).
  • R 4 represents -N(R 29 )(R 2h ).
  • the pair of R 29 and R 2h together with the atom(s) to which they are attached, form a 4- to 6- membered heterocycloalkyl or heterocycloalkenyl group optionally substituted by one or more substituents selected from A 6 .
  • R 4 represents -N(R 29 )(R 2h ) wherein R 29 and R 2h together with the atom(s) to which they are attached do not form a ring.
  • R 4 represents Het 2 (e.g. wherein Het 2 is bound via a nitrogen atom), -OR 2a (e.g. -OH) or -N(R 29 )(R 2h ), wherein each of R 2a , R 29 and R 2h independently represent H or C alkyl optionally substituted by one or more A 5 , or alternatively the pair of R 29 and R 2h , together with the atom(s) to which they are attached, form a 4- to 6- membered (e.g. 5-membered) heterocycloalkyl group optionally substituted by one or more substituents selected from A 6 .
  • -OR 2a e.g. -OH
  • -N(R 29 )(R 2h ) independently represent H or C alkyl optionally substituted by one or more A 5
  • R 29 and R 2h together with the atom(s) to which they are attached, form a 4- to 6- membered (e.g. 5-membered) heterocycloal
  • the 5- membered heterocycloalkyl group formed by R 29 and R 2h is a pyrrolidine group.
  • a 6 represents fluoro or, particularly, -OR 3a .
  • R 3a represents Het 8 .
  • Het 7 represents a 5- to 6- membered heteroaryl group containing one or more heteroatoms and optionally substituted by one or more substituents selected from D 2 .
  • Het 7 represents pyrimidinyl optionally substituted by one or more substituents selected from fluoro and, particularly, -CN.
  • R 29 and R 2h both represent C1 -3 alkyl (e.g. C1 alkyl) optionally substituted by one or more fluoro, such as wherein R 29 and R 2h both represent methyl.
  • R 1 , R 29 and R 2h are as defined herein (i.e. in the first aspect of the invention, including all embodiments thereof).
  • R 1 may not represent H.
  • the compound of formula III is not a compound selected from the list consisting of:
  • that ring may not be a pyrrole.
  • R 29 and R 2h may not be joined together to form a ring (e.g. R 29 represents H).
  • R 29 and R 2h both represent methyl.
  • R 1 , R 2 , R 3 , R 4 and R 5 groups that may be mentioned include those present in the example compounds as described hereinafter.
  • R 1 and R 2 together form a 5 to 7 membered heterocycloalkyl, optionally substituted by one or more (e.g. one) Y 1 .
  • R 1 and R 2 may form a 5 to 7 membered heterocycloalkyl comprising a single heteroatom, for example oxygen, nitrogen and sulphur, such as nitrogen.
  • R 1 and R 2 may form a 5 to 7 membered heterocycloalkyl comprising a single heteroatom, wherein the hetero atom of the heterocycloalkyl is substituted by Y 1 .
  • R 1 and R 2 form a 6 membered heterocycloalkyl comprising a nitrogen atom. More particularly, R 1 and R 2 form a piperidinyl ring, which is thus fused to the essential pyrazolyl ring of the compounds of formula I.
  • R 1 and R 2 form a piperidinyl ring which is substituted at the nitrogen atom by Y 1 .
  • Y 1 represents -S(0) 2 R 4b or a Ci-e alkyl optionally substituted by one or more C 1 . In further embodiments, Y 1 represents a C1- 6 alkyl optionally substituted by a phenyl group.
  • Y 1 is a benzyl group.
  • R 3 represents H
  • R 5 represents H or fluoro
  • R 5 represents H
  • R 1 and R 2 form a 5 to 7 membered heterocycloalkyl
  • R 3 and R 5 are each H or fluoro.
  • R 1 and R 2 form a 5 to 7 membered heterocycloalkyl
  • R 3 and R 5 are each H.
  • R 1 and R 2 form a 5 to 7 membered heterocycloalkyl, optionally substituted by one or more Y 1 ;
  • R 4 is as defined herein (i.e. in the first aspect of the invention, including all embodiments thereof).
  • R 4 represents H or, particularly, a substituent selected from the group consisting of Het 2 , halo, -NO2, -OR 2a , -S(0) p R 2b , -S(0) q N(R 2c )(R 2d ), -N(R 2e )S(0) r R 2f and -N(R 29 )(R 2h ).
  • R 4 is a group bound to the remainder of the compound (i.e. bound to the core pyrazole moiety) via a heteroatom (e.g. via a nitrogen atom).
  • R 4 represents H or, particularly, a substituent selected from the group consisting of Het 2 (e.g. wherein Het 2 is bound via a nitrogen atom), -OR 2a (e.g. -OH) and -N(R 29 )(R 2h ).
  • the -N(R 29 )(R 2h ) group is a -NHR 2h group (i.e. R 29 represents H) , such as wherein R 2h represents C1-3 alkyl (e.g. C1-2 alkyl) optionally substituted with one or more A 5 (such as wherein A 5 represents Ar 5 , Het 5 , halo, -OR 3a , -N(R 39 )R 3h , -C(0)0R 3i or -C(0)NR 3j R 3k .
  • the Het 2 group may in particular represent a 5- to 14- membered heteroaryl group (e.g. a 5- to 6- membered heteroaryl group) optionally substituted by one or more substituents selected from B 2 .
  • R 4 represents H or, particularly, a substituent selected from the group consisting of -OR 2a and -N(R 29 )(R 2h ).
  • R 4 represents -N(R 29 )(R 2h ).
  • the pair of R 29 and R 2h together with the atom(s) to which they are attached, form a 4- to 6- membered heterocycloalkyl or heterocycloalkenyl group optionally substituted by one or more substituents selected from A 6 .
  • R 4 represents -N(R 29 )(R 2h ) wherein R 29 and R 2h together with the atom(s) to which they are attached do not form a ring.
  • R 4 represents Het 2 (e.g. wherein Het 2 is bound via a nitrogen atom), -OR 2a (e.g. -OH) or -N(R 29 )(R 2h ), wherein each of R 2a , R 29 and R 2h independently represent H or Ci-e alkyl optionally substituted by one or more A 5 , or alternatively the pair of R 29 and R 2h , together with the atom(s) to which they are attached, form a 4- to 6- membered (e.g. 5-membered) heterocycloalkyl group optionally substituted by one or more substituents selected from A 6 .
  • a 4- to 6- membered e.g. 5-membered
  • the 5- membered heterocycloalkyl group formed by R 29 and R 2h is a pyrrolidine group.
  • a 6 represents fluoro or, particularly, -OR 3a .
  • R 3a represents Het 8 .
  • Het 7 represents a 5- to 6- membered heteroaryl group containing one or more heteroatoms and optionally substituted by one or more substituents selected from D 2 .
  • Het 7 represents pyrimidinyl optionally substituted by one or more substituents selected from fluoro and, particularly, -CN.
  • R 29 and R 2h both represent C 1-3 alkyl (e.g. C 1 alkyl) optionally substituted by one or more fluoro, such as wherein R 29 and R 2h both represent methyl.
  • R 1 and R 2 form a 5 to 7 membered heterocycloalkyl, optionally substituted by one or more Y 1 ;
  • R 29 and R 2h are as defined herein (i.e. in the first aspect of the invention, including all embodiments thereof).
  • R 29 and R 2h are joined together to form a ring, that ring may not be a pyrrole.
  • that ring may not be a heteroaryl group.
  • R 29 and R 2h may not be joined together to form a ring (e.g. R 29 represents H).
  • R 29 and R 2h both represent methyl.
  • R 1 , R 2 , R 3 , R 4 and R 5 groups that may be mentioned include those present in the example compounds as described hereinafter.
  • Particular compounds of the first aspect of the invention include those described in the examples provided herein, and pharmaceutically acceptable salts and/or prodrugs (e.g. pharmaceutically acceptable salts) thereof.
  • references to such compounds also include references to the free (i.e. non-salt) form of said compound (e.g. the free base) and all possible pharmaceutically acceptable salts thereof.
  • references to such compounds also include references to the free (i.e. non-salt) form of said compound (e.g. the free base) and all possible pharmaceutically acceptable salts thereof.
  • more particular forms of the compounds as described in the examples provided herein are those in the salt or non-salt form as described.
  • the term“patient” will be understood to refer to the subject being treated or, similarly, the subject benefiting from the preventative measure.
  • the term “patient” includes mammalian patients (such as equines, cattle, swine, sheep, goats, horses, primates, mice, rats, and pets in general including dogs, cats, guinea pigs, ferrets, and rabbits).
  • the term“patient” refers to humans.
  • compounds of the first aspect of the invention may possess pharmacological activity as such, there may be certain compounds which may not possess such activity, but may be administered parenterally or orally and thereafter be metabolized in the body to form active compounds.
  • compounds mentioned in respect of the first aspect of the invention are useful because they possess pharmacological activity, and/or are metabolized in the body following oral or parenteral administration to form compounds, which possess pharmacological activity.
  • the present invention encompasses the use of prodrugs of compounds as described herein (e.g. compounds of the first aspect of the invention).
  • esters of such compounds include esters of such compounds (i.e. esters formed by reaction of the compound of invention to form an ester comprising that compound).
  • the references to esters of compounds of the invention may refer to pharmaceutically-acceptable esters as known to those skilled in the art, such as Ci -4 alkyl esters.
  • such esters may include those formed by reaction of the essential hydroxyl moiety present on the core pyrazole group of compounds of the invention to form an ester thereof (e.g. so forming a -OWi group, wherein Wi may represent Ci -4 alkyl optionally substituted by one or more fluoro).
  • Particular esters that may be mentioned include methyl, ethyl and t-butyl (i.e. pivaloyl) esters.
  • prodrugs of compounds of the invention include carbonate esters of such compounds (i.e. carbonate esters formed by reaction of the compound of invention to form a carbonate ester comprising that compound).
  • carbonate esters of compounds of the invention may refer to pharmaceutically-acceptable carbonate esters as known to those skilled in the art, such as C 1-4 alkyl esters.
  • Particular esters that may be mentioned include methyl, ethyl and t- butyl (i.e. pivaloyl) esters.
  • therapeutically effective amount refers to an amount of a compound which confers a therapeutic effect (e.g. the relevant treatment or prevention, such as the relevant treatment) on the treated patient (i.e. the patient (e.g. the mammal) to which the compound is administered).
  • the effect may be objective (i.e. measurable by some test or marker, such as the measurable treatment of the condition or the identifiable prophylaxis of the condition) or subjective (i.e. the subject gives an indication of or feels an effect).
  • a therapeutically effective amount of a compound according to the present invention is an amount sufficient to cure, alleviate or partially arrest the clinical manifestations of a given disease or disorder and its complications.
  • suitable daily doses may be in the range of about 10 to 2000 mg per patient, administered in single or multiple doses (for example, administered as three daily doses of 200 to 500 mg/kg, such as three daily doses of around 400 mg/kg).
  • the compounds of the invention may be administered in doses of 10 to 3000 mg, such as 50 to 2500 mg, or such as 10 mg to 2000 mg per day (for example, until such time as said treatment is no longer required).
  • Compounds of the first aspect of the invention may provide systemic and/or local (e.g. topical) therapeutic effects.
  • the treatment may involve systemic or local (e.g. topical) administration of a compound of the first aspect of the invention (including all embodiments thereof).
  • Particular forms of local administration include topical administration, for example to an area of the skin or a mucous membrane of the body (including internal and external mucous membranes).
  • Compounds of the first aspect of the invention may be administered orally, intravenously, subcutaneously, buccally, rectally, dermally, nasally, tracheally, bronchially, by any other parenteral route or via inhalation, in a pharmaceutically acceptable dosage form.
  • compounds of the first aspects of the invention may be administered topically (i.e. applied directly to the area to be treated, as defined herein, or where prevention, as defined herein, is required).
  • the skilled person will be able to select the route of administration depending on the nature of the infection to be treated or prevented.
  • the compound may be administered by inhalation (and a suitable inhalable formulation used).
  • the compound may be administered topically to the relevant area (and a suitable topical formulation used, such as a pessary).
  • treatment or prevention as described herein may further comprise treatment or prevention with one or more active ingredient, wherein the term “administration” includes separate, sequential and/or simultaneous administration of the additional (i.e. other) active ingredient.
  • the treatment or prevention is of a fungal infection.
  • fungal infection refers to infection with one or more fungi, fungal-like species and/or parasite (e.g. one or more fungi).
  • fungi fungi, fungal-like species and/or parasite (e.g. one or more fungi).
  • parasite e.g. one or more fungi.
  • infections may be systemic and/or local.
  • bacterial infection refers to infection with one or more bacterial species.
  • the skilled person will understand that such infections may be systemic and/or local.
  • treatment takes its normal meaning in the field of medicine.
  • the term may refer to achieving a reduction in the severity of one or more clinical symptom associated with the disease or disorder (e.g. the fungal infection), as may be determined using techniques known to those skilled in the art (for example, by a medical physician).
  • the term may refer to killing and/or inhibiting or reducing growth of the fungi, fungal-like species and/or parasite (e.g. the fungal cells) associated with the infection.
  • treatment and “treating” may refer to achieving a reduction of colony forming units (CFUs) associated with the fungi, fungal-like species and/or parasite (e.g. the fungal cells), which may be determined through analysis of samples of bodily fluid (e.g. blood and/or urine) taken from the patient subjected to said treatment (e.g. comparison of samples taken before and after said treatment) using techniques known to those skilled in the art.
  • CFUs colony forming units
  • the treatment or prevention is of a bacterial infection.
  • the term may refer to killing and/or inhibiting or reducing growth of bacterial species associated with the infection.
  • prevention includes references to the prophylaxis of the disease or disorder (and vice- versa).
  • references to prevention may also be references to prophylaxis, and vice versa.
  • the term may refer to achieving a reduction in the likelihood of the patient (or healthy subject) developing the condition (for example, at least a 10% reduction, such as at least a 20%, 30% or 40% reduction, e.g. at least a 50% reduction).
  • references herein throughout to treating or preventing may refer in particular to treating (or, similarly, to treatment).
  • references herein to a fungal infection will refer to a (systemic or local, e.g. systemic) infection caused by one or more species of fungus as known to those skilled in the art.
  • the fungal infection is an infection caused by one or more (e.g. one) species of fungus selected from the group consisting of: Acremonium spp. (e.g. A. recifei or A. alabamense), Acrophialophora spp. (e.g. A. fusispora or A. levis), Alternaria spp. (e.g. A. infectoria, A. alternata), Aphanoascus fulvescens, Apophysomyces spp. (A. elegans or A. variabilis), Arthroderma spp. (e.g. A. insingulare or A.
  • Acremonium spp. e.g. A. recifei or A. alabamense
  • Acrophialophora spp. e.g. A. fusispora or A. levis
  • Alternaria spp. e.g. A. infectoria, A.
  • Aspergillus spp. e.g. A. clavatus, A. flavus, A. fumigatus, A. felis, A. nidulans, A. niger, A. terreus, A. lentulus or A. versicolor
  • Aureobasidium pullulans e.g. B. australiensis, B. hawaiiensis orB. spicifera
  • Blastomyces spp. e.g. B. dermatitidis
  • Blastoschizomyces e.g. B. capitatus
  • Botrytis cinerea Candida spp. (e.g. C. albicans, C.
  • C. oxysporum e.g. C. oxysporum
  • C. sphaerospermum e.g. C. devriesii
  • Cladophialophora spp. e.g. C. bantiana
  • Clavispora lusitaniae e.g. C. bantiana
  • Coccidioides e.g. C. immitis, C. posadasii
  • Cokeromyces recurvatus etotrichum spp.
  • Conidiobolus spp. e.g. C. coronatus, C. incongruus or C. lamprauges
  • Coniochaeta spp. e.g. C. C.
  • Cryptococcus spp. e.g. C. albidus, C. laurentii or C. neoformans (like var. neoformans or vargattii)
  • Cunninghamella spp. e.g. C. berthollethiae or C. elegans
  • Curvicularia lunata e.g. C. berthollethiae or C. elegans
  • Curvicularia lunata e.g. E. dermatitidis, E. jeanselmei, E. oligosperma, E. phaeomuriformis E. spinifera orE. xenobiotica
  • Fonsecaea spp. e.g. F. compacta, F. monophora, or F. pedrosi
  • Fusarium spp. e.g. F. oxysporum, F. solani, F. verticillioides, F. chlamydosporum, F. dime rum, F. fujikuroi, or F. incarnatum
  • Geotrichum spp. e.g. G. candiddum, G. capitatum or G.
  • M. globosa or M. furfur Malassezia spp.
  • Microsphaeropsis arundinis Microsporum spp.
  • M. audouinii M. canis
  • M. ferrugineum M. cookei
  • M. gallinae M. vanbreuseghemii
  • Mortierella wolfii Monilinia spp.
  • Mucor e.g. M. amphibiorum, M. circinelloides, M. indicus, M. irregularis or M.
  • ramosissimus Myrmecridium schulzeri Nannizzia spp. (e.g. N. fulva, N. gypsea, N. nana or N. persicolor), Neosartorya fischeri, Neoscytalidium dimidiatum, Onychocola canadensis, Paecilomyces spp. (e.g. P. marquandii, P. variotii or P. lilacinus), Paracoccidioides (e.g. P. brasiliensis), Penicillium (e.g. P. marneffei), Phaeoacremonium spp. (e.g. P. P.
  • Pseudallescheria spp. e.g. P. boydii, Puccinia arachidis
  • Pyricularia spp. Pythium spp.
  • P. insidiosum P. aphanidermatum and P. ultimum
  • Quambalaria spp. e.g. Q. cyanescens, Q. pitereka, Q. eucalypti, Q. coyrecup or Q. simpsonii
  • Rhinocladiella spp. e.g. R. atrovirens or R.
  • Rhizoctonia solani Rhizomucor spp.
  • Rhizomucor spp. e.g. R. miehei or R. pusillus
  • Rizopus spp. e.g. R. micropsorus, R. oryzae, R. pusillus
  • Rhodotorula spp. e.g. R. glutinis orR. mucilaginosa
  • Saccharomyces e.g. S. cerevisiae
  • Saksenaea vasiformis Scedosporium spp. (e.g. S. apiospermum, S. auraticum, S. boydii or S.
  • Trichosporon spp. e.g. T. asahii, T. asteroids, T. beigelii, T. cuaneum, T. inkin, T. ovoides, T. roseum or T. terrestre
  • Uncinula necator syn. Erysiphe necator
  • Venturia spp. Veronaea botryose
  • Verruconis spp. e.g. V. gallopava
  • Wickerhamomyces anomalus e.g. V. gallopava
  • fungus particularly species include C. albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, A. fumigatus, A. flavus, A. terms, F. solani, F. verticillioides, F. Oxysporum, Mucor spp. and Cryptococcus spp.
  • references to particular species of fungi may also include references to naturally-ocurring mutant forms thereof, as known to those skilled in the art.
  • compounds of the first aspect of the invention may be useful for the treatment and/or prevention of a variety of superficial, cutaneous, subcutaneous fungal infections, such as systemic mycotic infections in skin, eye, hair, nail, oral mucosa, gastrointestinal tract, bronchus, lung, endocardium, brain, meninges, urinary organ, vaginal portion, oral cavity, ophthalmus, systemic, kidney, heart, external auditory canal, bone, nasal cavity, paranasal cavity, spleen, liver, hypodermal tissue, lymph duct, gastrointestine, articulation, muscle, tendon, interstitial plasma cell in lung, blood and so on.
  • superficial, cutaneous, subcutaneous fungal infections such as systemic mycotic infections in skin, eye, hair, nail, oral mucosa, gastrointestinal tract, bronchus, lung, endocardium, brain, meninges, urinary organ, vaginal portion, oral cavity, ophthalmus, systemic, kidney, heart, external auditory canal, bone, nasal cavity
  • the treatment or prevention of a fungal infection may comprise (or consist of) the treatment or prevention of one or more condition selected from the group consisting of: dermatophytosis (e.g. trichophytosis, ringworm or tinea infections), athletes foot, paronychia, pityriasis versicolor, erytrasma, intertrigo, fungal diaper rash, Candida vulvitis, Candida balanitis, otitis externa, candidiasis (cutaneous and mucocutaneous), chronic mucocandidiasis (e.g.
  • dermatophytosis e.g. trichophytosis, ringworm or tinea infections
  • athletes foot paronychia
  • pityriasis versicolor erytrasma
  • intertrigo fungal diaper rash
  • Candida vulvitis Candida balanitis
  • otitis externa candidiasis (cutaneous and mucocutaneous)
  • chronic mucocandidiasis e.
  • thrush and vaginal candidiasis cryptococcosis, geotrichosis, trichosporosis, aspergillosis, penicilliosis, fusariosis, zygomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, histoplasmosis, blastomycosis, paracoccidioidomycosis, pseudallescheriosis, mycetoma, mycotic keratitis, otomycosis, pneumocystosis, rhinocerebral mucomycosis, lobomycosis, phaeohyphomycosis, and fugemia.
  • compounds of formula I may also be used as prophylactic agents to prevent fungal or bacterial infections (e.g. systemic and topical fungal or bacterial infections).
  • Use as prophylactic agents may, for example, be appropriate as part of a selective gut decontamination regimen in the prevention of infection in immune-compromised patients (e.g. AIDS patients, patients receiving cancer therapy or transplant patients). Further, prevention of fungal overgrowth during antibiotic treatment may also be desirable in some disease syndromes or iatrogenic states.
  • compounds of formula I, or pharmaceutically acceptable salts thereof may prevent fungal infections by hindering fungal biofilm formation.
  • compounds of formula I (as defined in the first aspect of the invention, including any one or more embodiment thereof), or pharmaceutically acceptable salts thereof, may also be used for the prevention or treatment of a bacterial infection.
  • the bacterial infection may be an infection with one or more (e.g. one) Gram-positive bacterial species. [Is this correct?]
  • the bacterial infection may be an infection with one or more (e.g. one) bacterial species selected from the following: [Please provide a list of relevant species]
  • the treatment or prevention comprises administering a therapeutically effective amount of a pharmaceutical formulation comprising a compound as defined in the first aspect of the invention (including all embodiments thereof), and optionally one or more pharmaceutically acceptable excipients.
  • Suitable pharmaceutically acceptable excipients will be well-known to those skilled in the art, and may include suitable adjuvants, diluents and carriers as known to those skilled in the art, such as those described herein.
  • pharmaceutical formulations that may be mentioned include those in which the active ingredient is present in at least 1% (or at least 10%, at least 30% or at least 50%) by weight. That is, the ratio of active ingredient to the other components (i.e. the addition of adjuvant, diluent and carrier) of the pharmaceutical composition is at least 1 :99 (or at least 10:90, at least 30:70 or at least 50:50) by weight.
  • compositions may be formulated to deliver the active ingredient (i.e. the compound of formula I, or pharmaceutically acceptable salt thereof) in a manner designed to provide systemic and/or local therapeutic effects.
  • compositions may be specifically formulated for administration by any suitable route, such as the oral, rectal, nasal, pulmonary, buccal, sublingual, transdermal, intracisternal, intraperitoneal, and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) route.
  • pharmaceutical compositions according to the first aspect of the invention may be specifically formulated for administration by the oral route. It will be appreciated that the preferred route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient chosen.
  • Pharmaceutical compositions for oral administration include solid dosage forms such as hard or soft capsules, tablets, troches, dragees, pills, lozenges, powders and granules. Where appropriate, they can be prepared with coatings such as enteric coatings, or they can be formulated so as to provide controlled release of the active ingredient, such as sustained or prolonged release, according to methods well known in the art.
  • Liquid dosage forms for oral administration include solutions, emulsions, aqueous or oily suspensions, syrups and elixirs.
  • compositions for parenteral administration include sterile aqueous and non-aqueous injectable solutions, dispersions, suspensions or emulsions, as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use. Depot injectable formulations are also regarded as being within the scope of the present invention.
  • Suitable administration forms include suppositories, sprays, ointments, creams, gels, inhalants, dermal patches and implants.
  • a typical oral dosage may be in the range from about 0.01 to about 500 mg/kg body weight per day, particularly from about 0.1 to about 200 mg/kg body weight per day, and more particularly from about 10 to about 100 mg/kg body weight per day, administered in one or more doses such as 1-3 doses.
  • doses such as 1-3 doses.
  • the exact dosage will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated, and other factors evident to those skilled in the art.
  • a typical unit dosage form for oral administration one or more times per day, such as 1-3 times per day, may contain from 0.05 to about 1000 mg, preferably from about 0.1 to about 500 mg, and more preferably from about 0.5 mg to about 200 mg of a compound of the invention.
  • typical dosages are in the order of about half the dosage employed for oral administration.
  • solutions of compounds may be administered in sterile aqueous solution, in aqueous propylene glycol or in sesame or peanut oil.
  • Aqueous solutions should be suitably buffered where appropriate, and the liquid diluent rendered isotonic with, e.g., sufficient saline or glucose.
  • Aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • the sterile aqueous media to be employed are all readily available by standard techniques known to those skilled in the art.
  • Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents.
  • solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatine, agar, pectin, acacia, magnesium stearate, stearic acid and lower alkyl ethers of cellulose.
  • liquid carriers are syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene and water.
  • the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
  • sustained release material such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
  • compositions suitable for oral administration may be presented as discrete units, such as capsules or tablets, which each contain a predetermined amount of the active ingredient, and which may include a suitable excipient.
  • the orally available formulations may be in the form of a powder or granules, a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsion.
  • compositions intended for oral use may be prepared according to any known method, and such compositions may contain one or more additional components selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • Tablets may contain the active ingredient(s) in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may, for example, be: inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example corn starch or alginic acid; binding agents, for example, starch, gelatine or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in U.S. Patent Nos. 4,356, 108; 4, 166,452; and 4,265,874, the contents of which are incorporated herein by reference, to form osmotic therapeutic tablets for controlled release.
  • a typical tablet is prepared by conventional tabletting techniques and contains the following.
  • Active compound (as free compound or salt thereof) 5.0 mg
  • the pharmaceutical composition comprising a compound according to the first aspect of the invention may additionally comprise further active substances.
  • the treatment or prevention as described in the first aspect of the invention may also comprise (i.e. as part of the same medical intervention) administration of one or more (e.g. one) additional (i.e. other) active substances.
  • such further active substances may include one or more agent selected from the group consisting of fungicidal and/or fungistatic agents, antibacterial agents, antiviral agents, antiseptics, analgesics and anaesthetics (e.g. local anaesthetics), as known to those skilled in the art.
  • such further active substances may include one or more (additional) anti-fungal agent, as known to those skilled in the art.
  • amphotericin B and any suitable formulations of amphotericin, such as amphotericin deoxycholate, amphotericin B lipid complex, amphotericin B cholesteryl sulfate complexes, amphotericin B colloidal dispersions, and liposomal amphotericin B formulations, as well as echinocandins such as caspofungin, micafungin, and anidulafungin.
  • amphotericin B and any suitable formulations of amphotericin such as amphotericin deoxycholate, amphotericin B lipid complex, amphotericin B cholesteryl sulfate complexes, amphotericin B colloidal dispersions, and liposomal amphotericin B formulations, as well as echinocandins such as caspofungin, micafungin, and anidulafungin.
  • Formulations for oral use may also be presented as hard gelatine capsules where the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or a soft gelatine capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil medium for example peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions may contain the compound as described in the first aspect of the invention (including all embodiments thereof) in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients may include suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide such as lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, heptadecaethyl-eneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids
  • oily suspensions may be formulated by suspending the active ingredient(s) in a vegetable oil, for example arachis oil, olive oil, sesame oil, corn oil, or coconut oil, or in a mineral oil such as a liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation.
  • These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active compound in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • a dispersing or wetting agent e.g., talc, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol
  • compositions comprising a compound of the first aspect of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, for example, olive oil or arachis oil, or a mineral oil, for example a liquid paraffin, or a mixture thereof.
  • Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavouring agents.
  • syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavouring and colouring agent.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known methods using suitable dispersing or wetting agents and suspending agents described above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1 ,3-butanediol.
  • compositions may also be provided in the form of suppositories for rectal administration. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will thus melt in the rectum to release the drug.
  • suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will thus melt in the rectum to release the drug.
  • suitable non-irritating excipient include, for example, cocoa butter and polyethylene glycols.
  • compositions for buccal and sublingual use include mouth washes and gargles.
  • compounds of the first aspect of the invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
  • Liposomes may be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.
  • compounds of the first aspect of the invention may form solvates with water or common organic solvents. Such solvates are also encompassed within the scope of the invention.
  • the preparation may be tabletted, placed in a hard gelatine capsule in powder or pellet form, or may be in the form of a troche or lozenge.
  • the amount of solid carrier will vary widely, but will usually be from about 25 mg to about 1 g.
  • the preparation may be in the form of a syrup, emulsion, soft gelatine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
  • pharmaceutical formulations comprising compounds of the first aspect of the invention (including all embodiments thereof) may also be formulated for topical administration.
  • the pharmaceutical formulation as described herein is a topical pharmaceutical composition.
  • the term“topica includes references to formulations that are adapted for application to body surfaces (e.g. the skin or mucous membranes).
  • Mucous membranes that may be mentioned in this respect include the mucosa of the vagina, the penis, the urethra, the bladder, the anus, the mouth (including the mucosa of the cheek, the soft palate, the under surface of tongue and the floor of the mouth), the nose, the throat (including the mucosa of the pharynx, the larynx, the trachea and the esophagus), the bronchi, the lungs, the eye and the ear.
  • Topical compositions which are useful for treating disorders of the skin or of membranes (e.g. membranes accessible by digitation, such as membranes of the mouth, vagina, cervix, anus and rectum), include creams, ointments, lotions, sprays, gels and sterile aqueous solutions or suspensions.
  • topical compositions include those in which the active ingredient(s) is (are) dissolved or dispersed in a dermatological vehicle known in the art (e.g. aqueous or non-aqueous gels, ointments, water-in-oil or oil-in-water emulsions).
  • Constituents of such vehicles may comprise water, aqueous buffer solutions, non-aqueous solvents (such as ethanol, isopropanol, benzyl alcohol, 2-(2- ethoxyethoxy)ethanol, propylene glycol, propylene glycol monolaurate, glycofurol or glycerol), oils (e.g. a mineral oil such as a liquid paraffin, natural or synthetic triglycerides, or silicone oils such as dimethicone).
  • non-aqueous solvents such as ethanol, isopropanol, benzyl alcohol, 2-(2- ethoxyethoxy)ethanol, propylene glycol, propylene glycol monolaurate, glycofurol or glycerol
  • oils e.g. a mineral oil such as a liquid paraffin, natural or synthetic triglycerides, or silicone oils such as dimethicone.
  • the amount of the active compound used in topical compositions or combination products will depend, inter alia, upon the particular nature of the composition or combination product, as well as its intended use. In any event, those skilled in the art will be able to determine, by routine and non-inventive methods, amount that can be employed. Typically, however, the compound of formula I, or pharmaceutically acceptable salt thereof, will be present in the topical composition or combination product at from 0.01 to 25% by weight (e.g. from 0.1 to 10% by weight, such as from 0.1 to 5% by weight or, particularly, from 0.5 to 3% (e.g. 2% or 1 %) by weight) of the composition or product.
  • 0.01 to 25% by weight e.g. from 0.1 to 10% by weight, such as from 0.1 to 5% by weight or, particularly, from 0.5 to 3% (e.g. 2% or 1 %) by weight
  • topical pharmaceutical compositions such as creams, ointments, lotions, sprays and sterile aqueous solutions or suspensions are well known in the art. Suitable methods of preparing topical pharmaceutical compositions are described, for example in WO 95/10999, US 6,974,585, WO 2006/048747, as well as in documents cited in any of these references.
  • compounds of the invention may be utilized in reducing or preventing the growth of fungal or bacterial cells both in vivo and in vitro (i.e. ex vivo).
  • a method of killing and/or inhibiting or reducing growth of one or more fungal or bacterial cell comprising applying to said fungal or bacterial cell an effective amount of a compound as defined in the first aspect of the invention (including all embodiments thereof).
  • the method or use is an ex vivo (or in vitro) method or use.
  • a compound as defined in the first aspect of the invention (including all embodiments thereof) as an anti-fungal agent.
  • the use is an ex vivo use.
  • the compounds as defined in the first aspect of the invention are used to prevent or hinder fungal and/or bacterial biofilm formation.
  • compounds of the first aspect of the invention also have activity as agricultural agents, in particular in treating or preventing fungal infections in plants.
  • a method of treating or preventing a fungal infection in plants, plant material and/or plant propagation material comprising applying to the plant, plant material or plant propagation material or the locus thereof an effective amount of a compound of formula I as defined in the first aspect of the invention, or a salt thereof.
  • composition for use in treating or preventing a fungal infection in plants, plant material and/or plant propagation material comprising:
  • composition in treating or preventing a fungal infection in plants, plant material and/or plant propagation material, wherein the composition comprises:
  • a method of treating or preventing a fungal infection in plants, plant material and/or plant propagation material comprising applying to the plant, plant material or plant propagation material or the locus thereof an effective amount of:
  • fungal cell and “fungal cells” may refer to the cell of a fungi, fungal-like species and/or parasite (e.g. a fungi) as described in the first aspect of the invention (including any one or more embodiment thereof).
  • references to agents that kill fungal cells or inhibit or reduce growth of fungal cells include references to agents that are fungicidal and/or fungistatic.
  • the terms“killing” and“kill” when used in respect of fungal cells includes references to rendering said fungal cells inactive, for example such that the fungal cells are irreversibly rendered incapable of metabolism, growth and/or reproduction. Such an effect may also be described as fungicidal.
  • fungal cells may be killed by preventing, or disrupting, fungal biofilm formation.
  • the terms“killing” and“kill” when used in respect of bacteria cells includes references to rendering said bacteria cells inactive, for example such that the bacteria cells are irreversibly rendered incapable of metabolism, growth and/or reproduction. Such an effect may also be described as bactericidal.
  • bacetria cells may be killed by preventing, or disrupting, bacteria biofilm formation.
  • the terms“inhibiting or reducing growth” and “inhibit or reduce growth” includes references to reducing the rate at which one or more fungal cell (such as a colony consisting of multiple fungal cells) increases in size and/or number.
  • Such an effect may be determined by observing the size of individual fungal cells and/or the number of fungal cells forming a colony before and after treatment with a compound of the invention, using techniques known to those skilled in the art. Such an effect may also be described as fungistatic.
  • the fungal infection, fungus or fungal cell is of one or more (e.g. one) species as defined in the first aspect of the invention.
  • the fungal infection in plants, plant material and/or plant propagation material may be an infection caused by one or more (e.g. one) of the following plant pathogens: Blumeria graminis; Colletotrichium trifolii; Fusarium graminearium; Fusarium solani; Fusarium sporotriezes; Leptospharia nodorum; Magnaporthe grisea; Mycosphaerella graminicola; Neurospora crassa; Phytophthora capsid; Pyricularia oryzae; Pythium ultimum; Rhizoctonia solani; Trichophyton rubrum; and Ustilago maydis.
  • plant pathogens Blumeria graminis
  • Colletotrichium trifolii Fusarium graminearium; Fusarium solani; Fusarium sporotriezes
  • Leptospharia nodorum Magnaporthe grisea; Mycosphaer
  • Compounds may be assessed in respect of their activity in killing and/or inhibiting or reducing growth of one or more fungal or bacterial cell using techniques known to those skilled in the art, such as those described herein. For example, the ability of compounds to reduce or inhibit growth may be determined using the techniques described in the biological examples provided herein below. In this context, compounds may be considered to be effective in inhibiting or reducing growth of a given fungal strain if they are found to have a MIC50 (i.e. concentration delivering 50% growth inhibition) of less than or equal to 100 pg/mL (such as less than or equal to 50 pg/mL).
  • MIC50 i.e. concentration delivering 50% growth inhibition
  • compounds as described herein may be applied to control fungi in areas such as in the prevention of fungal infection in agriculture (e.g. in crop plants, such as those discussed herein, in wood and wood related technical products, in food storage and/or in hygiene management.
  • the present invention therefore specifically contemplates anti-fungal use, such as that described in respect of the third aspect of the invention, in these areas.
  • compounds of the invention may be characterised by being inhibitory or fungicidal at low rates of application, by being well tolerated by plants and by being environmentally safe. Therefore, compounds described herein may be used agrochemically to protect important crop plants against diseases that are caused by plant pathogenic fungi.
  • the term“treating” takes its normal meaning in the field of agriculture.
  • the term may refer to killing and/or inhibiting or reducing growth of the fungi, fungal-like species and/or parasite (e.g. the fungal cells) associated with the infection.
  • prevention includes references to the prophylaxis of the infection (and vice-versa).
  • the term may refer to achieving a reduction in the likelihood of the infection arising (for example, at least a 10% reduction, such as at least a 20%, 30% or 40% reduction, e.g. at least a 50% reduction).
  • the term“salt thereof” refers to any salt form suitable for use in the relevant method (i.e. suitable for use in agriculture) and may include those salts referred to herein as being“pharmaceutically acceptable” (as referred to in the first aspect of the invention).
  • the methods and compositions of the fourth and fifth aspects of the invention may utilise compounds of the first aspect of the invention (including all embodiments thereof).
  • the term“effective amount” refers to an amount of a compound which confers the desired (anti-fungal) effect on the recipient plant, plant material and/or plant propagation material (i.e. an amount that is capable of treating or preventing the fungal infection present in the plant, plant material and/or plant propagation material).
  • plants that may be mentioned include crop plants, such as: cereals (such as wheat, barley, rye, oat, rice, maize, and sorghum), beets (such as sugar beet and fodder beet), pomes, drupes, citrus and soft fruits (such as apples, pears, plums, peaches, almonds, cherries, oranges, lemons, grapefruits, mandarins, bananas, strawberries, raspberries, and blackberries), leguminous plants (such as beans, lentils, peas and soybeans), oil plants (such as rape, mustard, poppy, olives, sunflowers, coconut, castor oil plants, cocoa beans and groundnuts), cucumber plants (such as pumpkins, cucumbers and melons), fibre plants (such as cotton, flax, hemp and jute), vegetables (such as spinach, lettuce, asparagus, cabbages, carrots, onions, tomatoes, garlic, potatoes, eggplants and
  • plant material includes references to any material obtained and/or derived from a plant source (such as those plants mentioned herein), including food substances and structural materials (e.g. wood)
  • plant propagation material includes references to any material capable of being germinated and/or cultivated to produce a growing plant such as those plants mentioned herein), such as material in the form of seeds, tubers, bulbs, rhizomes and plant cuttings.
  • Compounds as described herein may also be applied to control fungi in related areas, including protection of technical materials, such as wood and wood related technical products, in food storage or in hygiene management.
  • compositions comprising compounds as described herein (e.g. compounds of the first aspect of the invention) can be applied to different plant parts such as fruits, blossoms, leaves, stems, tubers and roots.
  • Plant propagation material such as seeds, tubers, bulbs, rhizomes and plant cuttings may be coated by a liquid or solid formulation of the fungicide for protection against fungal infections, in particular against root pathogens, such as Pythium spp. and Phytophtora spp.
  • formulations containing compounds as described herein may be sprayed on growing plants to obtain a surface protection of leaves or by acquiring a systemic protection resulting in crop plants that are immune against plant pathogenic fungi at the whole plant level.
  • the systemic effect is obtained by plants through root uptake of the fungicide from the soil or by penetration through the cuticle layer and epidermis cells of leaves.
  • the present invention therefore specifically contemplates methods comprising all such forms of application (including any combination thereof).
  • compounds as described herein can be formulated to obtain a curative, preventive, or systemic effect on plants susceptible to various plant pathogenic fungi.
  • the preventive effect may be obtained by adding a formulation containing compounds described herein (e.g.
  • the soil prior to sowing e.g. the field where the crop plants will be cultivated or soil used for greenhouse production of vegetables or ornamentals. Young plants may be protected prior to transplantation by a total or partial treatment by immersion.
  • the present invention therefore specifically contemplates methods comprising these steps (optionally combined with the methods of application as known to those skilled in the art, such as discussed herein).
  • compounds as described herein When used in the treatment or prevention of infections, as anti-fungal agents or in killing or inhibiting the growth of fungal cells in plants, plant material and/or plant propagation material (e.g. as described herein), compounds as described herein may be administered as formulations or compositions suitable for such uses, such as those comprising one or more agriculturally acceptable carrier or diluent
  • compositions e.g. for treating a fungal infection in plants, plant material and/or plant propagation material as described in the fifth aspect of the invention
  • an agrochemical composition may be referred to as an agrochemical composition.
  • compounds as described herein may be formulated with an inert carrier in emulsifiable concentrates, coatable pastes, directly sprayable or dilutable solutions, dilute emulsions, wettable powders, soluble powders, dusts, granulates, as well as in encapsulations in e.g. polymeric substances.
  • the formulations may be further modified by addition of adjuvants such as stabilisers, antifoams, viscosity regulators, thickeners, binders, or tackifiers, depending on the desired properties.
  • the compound or the formulation of the compound may be added to fertilizers.
  • the composition may comprise at least one additional fungicidal and/or fungistatic compound in addition to the compound of formula I as described in the first aspect of the invention, or salt thereof.
  • compositions for treating a fungal infection in plants, plant material and/or plant propagation material comprising compounds of the invention may be applied by spraying, atomizing, dusting, scattering, coating or pouring, depending on the intended objectives and the prevailing circumstances.
  • the application to plants, plant material and/or plant propagation material may occur simultaneously or in succession with other compounds, such as fertilizers or micronutrients, or other substances influencing plant growth, as well as herbicides, insecticides, fungicides, bactericides, nematicides, molluscicides, or mixtures of several of these preparations.
  • the combination of several different active ingredients can be accompanied by further addition of carriers, surfactants or other adjuvants generally used in the art of formulation.
  • compositions are typically done, according to known protocols, by mixing or grinding of the compounds with adjuvants and extenders like solvents, solid carriers and optionally surface-active compounds (surfactants).
  • adjuvants and extenders like solvents, solid carriers and optionally surface-active compounds (surfactants).
  • compositions containing compounds as described herein may contain from 0.1 to 99% by weight, preferably from 0.1 to 95%, of the compound of formula I as defined in respect of the first aspect of the invention, or a salt thereof. Such compositions may also contain from 99.9 to 1 % by weight, preferably 99.9 to 5%, of a solid or liquid adjuvant, and from 0 to 25% by weight of a surfactant.
  • compositions of the fifth aspect of the invention may be formulated as concentrates (i.e. for dilution by an end user to provide a dilute formulation for application).
  • the amount to apply can be experimentally determined and may depend on type of action, the developmental stage of the crop plant as well as on the application location, timing, application method and amount of disease causing fungi and the severity of the fungal attack.
  • the rate of application may constitute from 5 g to 2 kg of active ingredient (a.i.) (i.e. the compound of formula I, or salt thereof) per hectare (ha), preferably from 10 g to 1 kg a.i. /ha or most preferably from 20 to 600 g a.i. /ha.
  • convenient application rates are from 10 mg to 1 g of active ingredient per kg of seeds.
  • compositions as described in respect of the fifth aspect of the invention may be used in methods and uses as described in the second, third and fourth aspects of the invention.
  • R 1 , R 29 and R 2h are as defined in the first aspect of the invention (including all embodiments thereof).
  • the compound of formula III is not a compound selected from the list consisting of:
  • compounds of formula III, or pharmaceutically acceptable salts thereof have uses in medicine, such as in the treating or prevention of fungal and/or bacterial infections.
  • compounds of the invention may be utilized in medicine (i.e. as pharmaceuticals), such compounds may be incorporated in pharmaceutical compositions.
  • a pharmaceutical formulation comprising a compound of formula III as described in the first aspect of the invention, or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable carrier or excipient.
  • R 1 and R 2 taken together, form a 5 to 7 membered heterocycloalkyl, optionally substituted by one or more Y 1 (as defined herein);
  • R 29 and R 2h are as defined herein (i.e. in the first aspect of the invention, including all embodiments thereof).
  • compounds of formula Ilia, or pharmaceutically acceptable salts thereof have uses in medicine, such as in the treating or prevention of fungal and/or bacterial infections.
  • a compound of formula Ilia as described in the first aspect of the invention or a pharmaceutically acceptable salt thereof, for use in medicine (or as a pharmaceutical).
  • compounds of the invention may be utilized in medicine (i.e. as pharmaceuticals), such compounds may be incorporated in pharmaceutical compositions.
  • a pharmaceutical formulation comprising a compound of formula Ilia as described in the first aspect of the invention, or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable carrier or excipient.
  • compounds of the first aspect of the invention may be commercially available and/or described in the literature, and may be prepared in accordance with techniques known to those skilled in the art.
  • compounds described herein are not previously disclosed (i.e. are novel), such as compounds of formula III and pharmaceutically acceptable salts thereof (as described in the first and sixth aspects of the invention, including all embodiments thereof).
  • novel compounds may be prepared in accordance with techniques known to those skilled in the art, such as those described herein after (e.g. in the examples).
  • LG 1 represents a suitable leaving group (e.g. a group of formula -OR za wherein R za represents C 1-3 alkyl optionally substituted by one or more fluoro, or halo), under conditions known to those skilled in the art, such as in the presence of a suitable solvent (e.g. a suitable alcohol, such as /so-propanol) and optionally at elevated temperature (i.e. at above room temperature, such as the reflux temperature of the solvent);
  • a suitable solvent e.g. a suitable alcohol, such as /so-propanol
  • elevated temperature i.e. at above room temperature, such as the reflux temperature of the solvent
  • LG 2 represents a suitable leaving group (e.g. a halo group, such as chloro), with a compound of formula VII
  • LG 4 represents a suitable leaving group, for example wherein one of LG 3 and LG 4 represents halo (such as iodo, chloro or, particularly, bromo) and the other represents - B(OH)2 or -B(OR zb )2, in which each R zb independently represents a C1-6 alkyl group or the respective R zb groups may be linked together to form a 4- to 6- membered cyclic group (such as a 4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl group), under conditions known to those skilled in the art, such as in the presence of a suitable catalyst (such as a palladium catalyst, for example a palladium (0) catalyst, e.g.
  • a suitable catalyst such as a palladium catalyst, for example a palladium (0) catalyst, e.g.
  • Pd(PPh3)4 and in the presence of a suitable base (such as a suitable carbonate, e.g. sodium carbonate or potassium carbonate), optionally as an aqueous solution, and optionally in the presence of a suitable solvent (such as 1 ,4-dioxane, toluene and/or ethanol);
  • a suitable base such as a suitable carbonate, e.g. sodium carbonate or potassium carbonate
  • a suitable solvent such as 1 ,4-dioxane, toluene and/or ethanol
  • phenyl optionally substituted by one or more fluoro, under conditions known to those skilled in the art, for example in the presence of a suitable aqueous base (such as an aqueous hydroxide salt, for example aqueous sodium hydroxide) and in the presence of a suitable solvent (such as a polar solvent, for example methanol);
  • a suitable aqueous base such as an aqueous hydroxide salt, for example aqueous sodium hydroxide
  • a suitable solvent such as a polar solvent, for example methanol
  • compounds of formula I may be prepared by reaction of a compound of formula IVa
  • LG 1a represents a suitable leaving group (e.g. a group as defined as LG 1 for compounds of formula V as hereinbefore defined), under conditions known to those skilled in the art, such as in the presence of a suitable solvent (e.g. a suitable alcohol, such as /so-propanol) and optionally at elevated temperature (i.e. at above room temperature, such as the reflux temperature of the solvent).
  • a suitable solvent e.g. a suitable alcohol, such as /so-propanol
  • elevated temperature i.e. at above room temperature, such as the reflux temperature of the solvent.
  • compounds of formula IV may be prepared by reaction of a compound of formula XI or a suitable salt and/or protected derivative thereof (e.g. a compound of formula XI wherein the hydrazine group is protected with a f-butylcarbonyl (Boc) group), wherein LG 5 represents a suitable leaving group (e.g. a halo group, such as chloro), with a compound of formula VII
  • R 29 and R 2h are as hereinbefore defined, under conditions known to those skilled in the art, such as in the presence of a suitable solvent (e.g. where R 29 and R 2h are both methyl, using the compound of formula VII as a solvent).
  • a suitable solvent e.g. where R 29 and R 2h are both methyl, using the compound of formula VII as a solvent.
  • compounds of formula IVa may be prepared by analogy with the processes used for the preparation of compounds of formula IV.
  • Substituents on alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl and heterocyclic groups in compounds of formula I may be introduced and/or intercon verted using techniques well known to those skilled in the art by way of standard functional groups interconversions, in accordance with standard techniques, from readily available starting materials using appropriate reagents and reaction conditions. For example, benzyloxy may be converted to hydroxy, etc.
  • Compounds of formula III (and, similarly, compounds of formula I and other compounds the preparation of which is described herein) may be isolated from their reaction mixtures using conventional techniques. For example, compounds of formula III may be isolated by conversion to an acid (e.g. hydrochloric acid) salt (e.g.
  • the salt can simply be washed with or slurried in the presence such a suitable solvent in order to isolate the pure acid salt of the compound of formula III.
  • compounds of formula III may also contain one or more asymmetric carbon atoms and may therefore exhibit optical and/or diastereoisomerism.
  • Diastereoisomers and enantiomers may be isolated using conventional techniques, e.g. chromatography. The various stereoisomers may be isolated by separation of a racemic or other mixture of the compounds using conventional, e.g. HPLC techniques. Alternatively the desired optical isomers may be made by reaction of the appropriate optically active starting materials under conditions which will not cause racemisation or epimerisation, or by derivatisation (for example with a homochiral acid), followed by separation of the diastereomeric derivatives by conventional means (e.g. fractional crystallisation, HPLC, chromatography over silica). All stereoisomers are included within the scope of the invention.
  • Functional groups that it may be desirable to protect include hydroxy, amino and carboxylic acid group.
  • suitable protecting groups for hydroxy groups include optionally substituted and/or unsaturated alkyl groups (e.g. methyl, allyl, benzyl or tert- butyl), trialkylsilyl or diarylalkylsilyl groups (e.g.
  • suitable protecting groups for carboxylic acid include Ci-e alkyl or benzyl esters
  • suitable protecting groups for amino include te/f-butyloxycarbonyl and benzyloxycarbonyl.
  • protection and deprotection of functional groups may take place before or after coupling, or before or after any other reaction in the above-mentioned schemes.
  • Protecting groups may be removed in accordance with techniques that are well known to those skilled in the art and as described hereinafter.
  • Protected derivatives of compounds of formula III may be converted chemically to compounds of the invention using standard deprotection techniques (e.g. hydrogenation).
  • the invention further provides a process for the preparation of a pharmaceutical formulation, as hereinbefore defined, which process comprises bringing into association a compound of formula II I, or a pharmaceutically acceptable salt thereof, as described in respect of the first aspect of the invention (including any one or more embodiment thereof), with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • compounds as described herein may have the advantage that they may be more convenient for the physician, patient or agrochemical user than, be more efficacious than, have less unwanted toxicity (e.g. mammalian, such as human, toxicity) than, have a broader range of activity than, be more potent than, produce fewer unwanted effects than, or may have other useful (e.g. pharmacological) properties over compounds known in the prior art as being useful in such methods and uses.
  • unwanted toxicity e.g. mammalian, such as human, toxicity
  • All microbial cells need zinc for growth, although the concentrations required may be very low.
  • Beside ZIP family uptake transporters some fungal species possess additional mechanisms to sequester zinc from host cells and tissues in a process analogous to iron chelation by secreted siderophores.
  • C. albicans secretes the antigenic protein Pra1 , a zinc-binding protein that is able to scavenge zinc from tissues invaded by the fungus.
  • othologs of the gene encoding Pra1 are found in diverse fungal pathogens including A. fumigatus (the zinc-regulated aspf2 gene).
  • These zinc- sequestering genes are generally clustered with Zrt1 orthologs in these fungi in a highly syntenic fashion, representing a conserved mechanism for zinc acquisition during host- fungal interactions (see, for example, Pope et ai, Mini Review Article “Fungal zinc metabolism and its connections to virulence” (2013), and Citiulo et ai, PLoS Pathogens, (2012)).
  • SOD Cu/Zn superoxide dismutase
  • alcohol dehydrogenase ribosomes.
  • SODs are the central enzymes in fungi associated with the detoxification of ROS generated by host cells during host-pathogen interactions. In this view, specific SODs from pathogenic fungi are assumed to be virulence determinants.
  • compounds as described herein may have the advantage that they may be more efficacious than, be less toxic than, be longer acting than, be more potent than, produce fewer side effects than, be more easily absorbed than, and/or have a better pharmacokinetic profile (e.g. higher oral bioavailability and/or lower clearance) than, and/or have other useful pharmacological and/or agricultural, physical, or chemical properties over, compounds known in the prior art (whether such compounds are known in the prior art for use in the above-stated indications or otherwise).
  • pharmacokinetic profile e.g. higher oral bioavailability and/or lower clearance
  • STKED20 buffer Sucrose-Tris-HCI-KCI-EDTA-glucose buffer 200 g/L sucrose, 40 g/L glucose, 50 mM Tris-HCI pH 7.25, 50mM KCI, 1 mM EDTA pH 8.0, 1 mM DTT, 0.2 mM PMSF, 2 pg/ml Pepstatin A)
  • YPD medium Yeast-peptone-glucose medium (10 g/L yeast extract, 20 g/L bacto-peptone, 20 g/L glucose, 20 g/L agar)
  • Purification by chromatography refers to purification using either the CombiFlash® Companion purification system or the Biotage Isolera® purification systems.
  • Isolute SPE Si cartridge refers to a pre-packed polypropylene column containing unbonded activated silica with irregular particles with average size of 50 pm and nominal 60A porosity.
  • thin layer chromatography TLC
  • it refers to silica gel TLC using plates, typically silica gel on aluminium foil plates with a fluorescent indicator (254 nm, e.g. Fluka 60778).
  • Microwave reactions were carried out using a Biotage Initiator 60TM which uses a single mode resonator and dynamic field tuning. Temperature from 40-250 °C can be achieved, and pressures of up to 30 bar can be reached.
  • Mass Directed Auto-Purification was used to purify compounds where indicated. Separation using Agilent 1260 Infinity Purifications System, XSelect CSH Prep C18 5 pm, 21 x 250 mm (acidic modifier) or XBridge Prep C18 5 pm, 21 c 250 mm as the stationary phase, maintained at RT and a 19 mL/min flow.
  • the initial solvent system was 90% water and 10% acetonitrile followed by a gradient up to 5% water and 95% acetonitrile (containing either 0.1 % formic acid or ammonium hydroxide modifiers), centred around a specific focused gradient, over 22 min.
  • Product collection was triggered by an Agilent 6100 series single Quadrupole LC/MS. The desired fractions were concentrated in vacuo at 40 °C.
  • Phase separator cartridges are supplied by Biotage® as Isolute® phase separator cartridges.
  • reaction may vary in relation to reaction temperature, reagent/solvent amount, reaction time, work-up conditions and/or chromatographic purification conditions.
  • Impure material was repurified by column chromatography eluting with EtOAc/cHexane (0:100 to 50:50, each eluent containing 0.5% AcOH). Pure fractions from both columns were combined and evaporated to give a white solid (400 mg). This was recrystallised from 7 mL EtOAc to give the title compound as a white solid (112 mg, 5%).
  • Trifluoroacetic acid (32.3 ml_, 422 mmol) was added slowly to a solution of tert- butyl (3S)- 3-[(4-cyano-3-pyridyl)oxy]pyrrolidine-1-carboxylate (8.14 g, 28.1 mmol) in DCM (80 ml_) .
  • the reaction mixture was stirred at room temperature for 1 h then diluted with toluene and concentrated in vacuo.
  • the crude was loaded onto an SCX-2 cartridge (50 g) washing first with methanol then eluting with 2 M NH 3 in MeOH.
  • the reaction mixture was stirred at 100 °C for 3 h, and then concentrated in vacuo , diluted with DCM and the organic layer washed with water using a phase separator. The organic layer was concentrated in vacuo. The crude was then purified using MDAP to give the title compound as a red solid (13 mg, 9%).
  • reaction mixture was concentrated in vacuo and the oily residue was diluted with DCM and the organic layer washed with water using a phase separator. The organic layer was concentrated in vacuo then purified using MDAP to give the title compound as a colourless solid (8.0 mg, 14%).
  • 6-Hydrazino-N,N-dimethyl-pyrimidin-4-amine 150 mg, 0.98 mmol was added to a solution of ethyl 3-(4-cyanophenyl)-3-oxo-propanoate (276 mg, 1.27 mmol) in iPrOH (2.0 ml_).
  • the reaction mixture was stirred at 83°C for 1 h.
  • the precipitate formed during the reaction was collected by filtration then purified by column chromatography eluting with DCM/NH 3 2 M in MeOH (100:0 to 90: 10) to give the title compound as a yellow solid (52 mg, 17%).
  • 6-Hydrazino-N,N-dimethyl-pyrimidin-4-amine (0.40 g, 2.61 mmol) and methyl -3- methoxyprop-2-enoate (606 mg, 5.22 mmol) in MeOH (4 ml_) was heated to 130°C in the microwave for 1 h. Further methyl-3-methoxyprop-2-enoate (303 mg, 2.61 mmol) was added and reaction was heated at 130°C for a further 1 h. The reaction mixture was evaporated and purified by column chromatography eluting with DCM/NH3 2 M in MeOH (100:0 to 95:5).
  • 6-Hydrazino-N,N-dimethyl-pyrimidin-4-amine (0.10 g, 0.650 mmol) and ethyl 2-methyl-3- oxo-propanoate (102 mg, 0.780 mmol) in iPrOH (1.0 ml_) was heated to 120°C in the microwave for 3 h. The reaction was evaporated to 200 mg yellow gum, and purified by acidic MDAP to give the title material as an off white solid (68 mg, 47%).
  • 6-Hydrazino-N,N-dimethyl-pyrimidin-4-amine (0.10 g, 0.650 mmol) and ethyl 2-methyl-3- oxo-butanoate (122 mg, 0.850 mmol) in iPrOH (2.0 ml_) was heated to reflux under argon for 2.5 h.
  • the mixture was evaporated and purified by column chromatography eluting with DCM/MeOH (100:0 to 95:5), to give a sharp first peak and a larger broad second peak. The fractions of the second peak containing uncyclised intermediate were combined and evaporated. The residue was dissolved in iPrOH (2.0 ml_) and refluxed overnight.
  • Step 2 tert-butyl N-[[6-(5-oxabicyclo[4.2.0]octan-8-ylamino)pyrimidin-4- yl]amino]carbamate
  • Step 4 Compound 225 (6-benzyl-2-[6-(5-oxabicyclo[4.2.0]octan-8-ylamino)pyrimidin-4- yl]-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-3-ol dihydrochloride)
  • Step 3 Common intermediate 228-A (ethyl 3-(2,4-dimethylthiazol-5-yl)-3-oxo-propanoate)
  • Tetrahydrofuran (500 ml_) and potassium t-butoxide 57.8g; 0.52 mol) were added to a reactor and cooled to -5°C.
  • 1-(2,4-dimethylthiazol-5-yl)ethanone (40g, 258 mmol) and diethyl carbonate (30.4g, 258mmol) in 25 ml_ of tetrahydrofuran was dropwise added to the reactor for 30 minutes and stirred at a temperature of 20 to 25 C overnight.
  • the organic layer was concentrated to a volume of 100 ml_ and this was poured into 500 ml_ of water and AcOH (2.5 equiv) was added thereto.
  • the mixture was finally extracted with 2x200 ml of EtOAc.
  • the resultant extract was dried and evaporated yielding the title compound.
  • Step 4 5-(2,4-dimethylthiazol-5-yl)-2-[6-(3-oxa-9-azaspiro[5.5]undecan-9-yl)pyrimidin-4- yl]pyrazol-3-ol
  • Step 1 ethyl 3-(2,4-dimethylthiazol-5-yl)-3-hydroxy-2-methyl-propanoate
  • Step 2 ethyl 3-(2,4-dimethylthiazol-5-yl)-2-methyl-3-oxo-propanoate was obtained
  • Step 1 (4,6-dichloropyrimidin-2-yl)methyl acetate
  • Kd dissociation constant
  • the minimum inhibitory concentration is here defined as the compound concentration that results in 50% growth reduction of a fungal isolate when exposed to an antifungal agent.
  • MICs are determined according to the reference procedure of the Antifungal Susceptibility Testing Subcommittee, EUCAST E.DEF 7.1 (Anon, EUCAST definitive document EDef 7.1 : method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 14(4), 398-405 (2008); available at: http://www.ncbi.nlm.nih.gov/pubmed/18190574).
  • MICs are determined according to the reference procedure of the Antifungal Susceptibility Testing Subcommittee, EUCAST E.DEF 9.1 (Arendrup, M.C. et ai, EUCAST DEFINITIVE DOCUMENT E . DEF 9 . 1 : Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. (July), .1-13 (2008)) for spore-forming moulds.
  • the fungal inocula are prepared from the species Candida albicans SC5314; Candida krusei ATCC6258, Candida parapsilosis ATCC22019, Candida glabrata ATCC90030, Candida glabrata Bra03, Candida tropicalis E1 -7276125B, Aspergillus fumigatus ATCC46645, Aspergillus terreus At070, Aspergillus flavus ATCC15547, Fusarium solani DSMZ10696, Fusarium verticillioides MYA-3629 and Cryptococcus neoformans DSM11959.
  • the fungal inoculum size is between 1x10 5 cfu/mL and 2.5x10 5 cfu/mL and the inoculum is prepared directly from subcultures of the various fungal strains grown on YPD or SD media at 35°C. .
  • Fungus, compound and growth medium are incubated in microtiter plates without agitation at 35 ⁇ 2°C 24hrs for yeast and 72hrs for moulds.
  • the endpoint is spectrophotometric recordings at OD 490nm.
  • a cell survival XTT assay This is a colorimetric assay that detects the cellular metabolic activity of the mammalian Hep G2 cell line after pre-incubation with a dilution series of NCE for either 24 or 72 hrs. Subsequent incubation of the exposed cells with the yellow tetrazolium salt XTT for 2-3 hrs allows enough time for metabolically active cells to reduce XTT to a highly colored dye. This conversion occurs only in viable cells so the amount of color produced is proportional to cell viability in the sample and endpoint is measured spectrophotometrically at OD450 nm for IC50 determination. Tamoxifen is used as a positive control compound and DMSO as negative control.
  • Balb/c mice are infected with 0.1 ml_ of inoculum of Candida albicans SC5314 by intravenous route on day 0. NCE are tested in 2 doses; low and high dose. Administration of NCE is initiated 24 hr prior (day -1) to infection (day 0) by intraperitoneal route, b.i.d. treatment for 4 days (day -1 to day 2). Inoculum: 1-5 x 10 5 CFU per animal. Control compound: Fluconazole. Sample collection and processing: 12 hours post last dose all treated and untreated animals are sacrificed by cervical dislocation and kidneys are collected in 3ml of sterile normal saline. The samples are homogenized, diluted serially and plated on SDA.
  • the cell survival window measured as 50% growth inhibition of C. albicans and 50% growth inhibition HepG2 cells, in the presence of compound 4 was found to be 40-fold

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé de formule (I) ou un sel pharmaceutiquement acceptable et/ou un promédicament de celui-ci, destinés à être utilisés dans le traitement ou la prévention d'une infection fongique ou bactérienne, dans la formule, R1 à R5 sont tels que définis dans la description. L'invention concerne également certains composés et procédés de préparation associés.
PCT/GB2018/050171 2018-01-19 2018-01-19 Dérivés d'hydroxy pyrazole n-pyrimidinyle et utilisations associées WO2019141957A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/GB2018/050171 WO2019141957A1 (fr) 2018-01-19 2018-01-19 Dérivés d'hydroxy pyrazole n-pyrimidinyle et utilisations associées

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2018/050171 WO2019141957A1 (fr) 2018-01-19 2018-01-19 Dérivés d'hydroxy pyrazole n-pyrimidinyle et utilisations associées

Publications (1)

Publication Number Publication Date
WO2019141957A1 true WO2019141957A1 (fr) 2019-07-25

Family

ID=61028088

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2018/050171 WO2019141957A1 (fr) 2018-01-19 2018-01-19 Dérivés d'hydroxy pyrazole n-pyrimidinyle et utilisations associées

Country Status (1)

Country Link
WO (1) WO2019141957A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210091063A (ko) * 2020-01-13 2021-07-21 압타바이오 주식회사 신규한 피라졸 유도체
WO2021177160A1 (fr) * 2020-03-04 2021-09-10 日本曹達株式会社 Composé azole d'azinyl et agent de lutte contre les organismes nuisibles
CN114555581A (zh) * 2019-11-14 2022-05-27 优迈特株式会社 含氟吡唑化合物及其制备方法
CN115991698A (zh) * 2022-11-03 2023-04-21 广东中科药物研究有限公司 一种杂环化合物及其制备方法与应用
WO2023110869A1 (fr) * 2021-12-15 2023-06-22 Syngenta Crop Protection Ag Dérivés hétérocycliques bicycliques microbiocides

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4663327A (en) * 1984-05-23 1987-05-05 Bayer Aktiengesellschaft 1-heteroaryl-4-aryl-pyrazolin-5-ones
US4698344A (en) * 1984-11-28 1987-10-06 Bayer Aktiengesellschaft 1-Heteroaryl-4-aryl-pyrazolin-5-ones for use as medicaments
WO1995010999A1 (fr) 1993-10-22 1995-04-27 Smithkline Beecham Corporation Nouvelle composition
US6974585B2 (en) 2001-08-01 2005-12-13 Medlogic Global Limited Durable multi-component antibiotic formulation for topical use
WO2006048747A1 (fr) 2004-11-08 2006-05-11 Glenmark Pharmaceuticals Limited Compositions pharmaceutiques topiques contenant un compose anti-acne et un compose antibiotique
WO2008042639A1 (fr) 2006-10-02 2008-04-10 Irm Llc Composés et compositions utilisés en tant qu'inhibiteurs de protéine kinase

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4663327A (en) * 1984-05-23 1987-05-05 Bayer Aktiengesellschaft 1-heteroaryl-4-aryl-pyrazolin-5-ones
US4698344A (en) * 1984-11-28 1987-10-06 Bayer Aktiengesellschaft 1-Heteroaryl-4-aryl-pyrazolin-5-ones for use as medicaments
WO1995010999A1 (fr) 1993-10-22 1995-04-27 Smithkline Beecham Corporation Nouvelle composition
US6974585B2 (en) 2001-08-01 2005-12-13 Medlogic Global Limited Durable multi-component antibiotic formulation for topical use
WO2006048747A1 (fr) 2004-11-08 2006-05-11 Glenmark Pharmaceuticals Limited Compositions pharmaceutiques topiques contenant un compose anti-acne et un compose antibiotique
WO2008042639A1 (fr) 2006-10-02 2008-04-10 Irm Llc Composés et compositions utilisés en tant qu'inhibiteurs de protéine kinase

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
ANON: "EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts", CLINICAL MICROBIOLOGY AND INFECTION: THE OFFICIAL PUBLICATION OF THE EUROPEAN SOCIETY OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES, vol. 14, no. 4, 2008, pages 398 - 405
ARENDRUP, M.C. ET AL., EUCAST DEFINITIVE DOCUMENT E . DEF 9 . 1 : METHOD FOR THE DETERMINATION OF BROTH DILUTION MINIMUM INHIBITORY CONCENTRATIONS OF ANTIFUNGAL AGENTS FOR CONIDIA FORMING MOULDS, 1 July 2008 (2008-07-01)
BOTELLA ET AL., CELL HOST AND MICROBE, vol. 10, no. 3, 2011, pages 248 - 259
CHAPMAN ET AL., TRANS AM CLIN CLIMATOL ASSOC., vol. 119, 2008, pages 197 - 215
CITIULO ET AL., PLOS PATHOGENS, 2012
DIMITRIOS K MATTHAIOU ET AL: "How to treat fungal infections in ICU patients", BMC INFECTIOUS DISEASES, BIOMED CENTRAL, LONDON, GB, vol. 15, no. 1, 2 May 2015 (2015-05-02), pages 205, XP021220914, ISSN: 1471-2334, DOI: 10.1186/S12879-015-0934-8 *
IBRAHIM, A. S., JOURNAL OF CLINICAL INVESTIGATION, vol. 117, no. 9, 2007, pages 2649 - 2657
J W F MCOMIE: "Protective Groups in Organic Chemistry", 1973, PLENUM PRESS
KRIENGKAUYKIAT ET AL., CLINICAL EPIDEMIOLOGY, vol. 3, 2011, pages 175 - 191
LULLOFF ET AL., JOURNAL OF LABORATORY AND CLINICAL MEDICINE, vol. 144, no. 4, 2004, pages 208 - 214
RIBAUD ET AL., CLIN INFECT DIS., vol. 28, 1999, pages 322 - 30
SANGUINETTI ET AL., ANTIMICROB AGENTS CHEMOTHER, vol. 49, 2005, pages 668 - 679
SNELDERS ET AL., FUTURE MICROBIOLOGY, vol. 6, 2011, pages 335 - 347
SPELLBERG B ET AL., CLIN MICROBIOL REV, vol. 18, no. 3, 2005, pages 556 - 569
STAATS ET AL.: "Mini Review Article", FUNGAL ZINC METABOLISM AND ITS CONNECTIONS TO VIRULENCE, 2013
T.W. GREENE; P.G.M. WUTZ: "Protective Groups in Organic Synthesis, 3rd ed.", 1999, WILEY-INTERSCIENCE
VIGNESH ET AL., IMMUNITY, vol. 39, no. 4, 2013, pages 697 - 710
YAPAR N., THERAPEUTICS AND CLINICAL RISK MANAGEMENT, vol. 10, 2014, pages 95 - 105

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114555581A (zh) * 2019-11-14 2022-05-27 优迈特株式会社 含氟吡唑化合物及其制备方法
CN114555581B (zh) * 2019-11-14 2024-05-24 优迈特株式会社 含氟吡唑化合物及其制备方法
KR20210091063A (ko) * 2020-01-13 2021-07-21 압타바이오 주식회사 신규한 피라졸 유도체
KR102333863B1 (ko) * 2020-01-13 2021-12-03 압타바이오 주식회사 신규한 피라졸 유도체
WO2021177160A1 (fr) * 2020-03-04 2021-09-10 日本曹達株式会社 Composé azole d'azinyl et agent de lutte contre les organismes nuisibles
WO2023110869A1 (fr) * 2021-12-15 2023-06-22 Syngenta Crop Protection Ag Dérivés hétérocycliques bicycliques microbiocides
CN115991698A (zh) * 2022-11-03 2023-04-21 广东中科药物研究有限公司 一种杂环化合物及其制备方法与应用
CN115991698B (zh) * 2022-11-03 2024-03-29 广东中科药物研究有限公司 一种杂环化合物及其制备方法与应用

Similar Documents

Publication Publication Date Title
WO2019141957A1 (fr) Dérivés d'hydroxy pyrazole n-pyrimidinyle et utilisations associées
US11001590B2 (en) Pyrazolopyrimidine derivatives
JP7165129B2 (ja) 新規な駆虫性キノリン－３－カルボキサミド誘導体
US8207187B2 (en) Use of pyrroloquinoline compounds to kill clinically latent microorganisms
US9409905B2 (en) Antibacterial compounds and methods for use
TWI827702B (zh) 新驅蟲化合物
JP7210483B2 (ja) 新規アザキノリン誘導体
ES2694637T3 (es) Agentes antifúngicos
EP3341007B1 (fr) Inhibiteurs de malt1 et leurs utilisations
JP2020528921A (ja) 蠕虫による感染を治療するためのキノリン誘導体
JP5548875B2 (ja) 抗真菌剤
US20100093691A1 (en) Topical formulations
JP7261747B2 (ja) 新規二環式ピラゾール誘導体
NO327312B1 (no) Gyraseinhibitorer og anvendelser derav
KR20160018811A (ko) 금속 효소 억제 화합물
KR20100021476A (ko) 임상적으로 잠복기 미생물을 사멸시키기 위한 ４­（피롤리딘­１­일）퀴놀린 화합물의 용도
TW200811194A (en) Antifungal agents
JPWO2012060448A1 (ja) 抗真菌剤としての併用医薬組成物
JP2023521342A (ja) 駆虫性化合物としての置換縮合アジン類
MX2011001656A (es) Agentes antifungicos.
EP3707141B1 (fr) 2,4-dihydro-3h-1,2,4-triazol-3-ones substituées et leur utilisation
EP2792360A1 (fr) (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide pour utilisation dans le traitement de HCV
WO2010003197A1 (fr) Dérivés de morpholine utilisés comme composés antifongiques
JP5548876B2 (ja) 抗真菌剤
CN109485607B (zh) β-唑类-苯基酮衍生物及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18701557

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18701557

Country of ref document: EP

Kind code of ref document: A1